Search results for " CD1"

showing 10 items of 47 documents

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19.

2021

ObjectiveTo evaluate the clinical consequences of extended interval dosing (EID) of ocrelizumab in relapsing-remitting multiple sclerosis (RRMS) during the coronavirus disease 2019 (COVID-19) pandemic.MethodsIn our retrospective, multicenter cohort study, we compared patients with RRMS on EID (defined as ≥4-week delay of dose interval) with a control group on standard interval dosing (SID) at the same period (January to December 2020).ResultsThree hundred eighteen patients with RRMS were longitudinally evaluated in 5 German centers. One hundred sixteen patients received ocrelizumab on EID (median delay [interquartile range 8.68 [5.09–13.07] weeks). Three months after the last ocrelizumab in…

0301 basic medicineAdultMalemedicine.medical_specialty41Antigens CD19MedizinLogistic regressionAntibodies Monoclonal HumanizedArticle2303 medical and health sciencesDisability Evaluation0302 clinical medicineMultiple Sclerosis Relapsing-RemittingInterquartile rangeInternal medicinemedicineHumansDosingLymphocyte CountPandemicsRetrospective Studies360B-Lymphocytes120business.industryMultiple sclerosisCOVID-19Retrospective cohort studyMiddle Agedmedicine.diseaseMagnetic Resonance Imaging030104 developmental biologyTreatment OutcomeNeurologyCohortOcrelizumabFemaleNeurology (clinical)business030217 neurology & neurosurgerymedicine.drugCohort studyNeurology(R) neuroimmunologyneuroinflammation
researchProduct

A two gene-based risk score predicts alcoholic cirrhosis development in males with at-risk alcohol consumption

2019

Rosellina Margherita Mancina,1,* Flaminia Ferri,2,* Alessio Farcomeni,3 Antonio Molinaro,1 Angela Maffongelli,4 Monica Mischitelli,2 Edoardo Poli,2 Lucia Parlati,5 Maria Antonella Burza,6 Adriano De Santis,2 Fabio Attilia,2 Claudia Rotondo,2 Maria Margherita Rando,2 Maria Luisa Attilia,2 Mauro Ceccanti,2 Stefano Ginanni Corradini2 1Department of Molecular and Clinical Medicine, The Sahlgrenska Academy at the University of Gothenburg, Wallenberg Laboratory, Göteborg, Sweden; 2Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy; 3Department of Public Health and Infectious Diseases, Sapienza University of Rome, Rome, Italy; 4Department of Gener…

0301 basic medicineAlcoholic liver diseasemedicine.medical_specialtylcsh:QH426-470AlcoholGastroenterologyPredictive score03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineGeneticsAllelePNPLA3Genetics (clinical)Original Researchlcsh:R5-920Framingham Risk ScoreReceiver operating characteristicbusiness.industryIncidence (epidemiology)Alcoholic cirrhosis; CD14; PNPLA3; Predictive score; Genetics; Genetics (clinical)medicine.diseaselcsh:Genetics030104 developmental biologyAlcoholic cirrhosischemistryThe Application of Clinical Geneticsbusinesslcsh:Medicine (General)Settore SECS-S/01 - StatisticaCD14Body mass index030217 neurology & neurosurgeryTM6SF2The Application of Clinical Genetics
researchProduct

CD1A-positive cells and HSP60 (HSPD1) levels in keratoacanthoma and squamous cell carcinoma.

2015

CD1a is involved in presentation to the immune system of lipid antigen derived from tumor cells with subsequent T cell activation. Hsp60 is a molecular chaperone implicated in carcinogenesis by, for instance, modulating the immune reaction against the tumor. We have previously postulated a synergism between CD1a and Hsp60 as a key factor in the activation of an effective antitumor immune response in squamous epithelia. Keratoacantomas (KAs) are benign tumors that however can transform into squamous cell carcinomas (SCCs), but the reasons for this malignization are unknown. In a previous study, we found that CD1a-positive cells are significantly more numerous in KA than in SCC. In this study…

0301 basic medicineKeratoacanthomaCellmedicine.disease_causeBiochemistryAntigens CD10302 clinical medicineSquamous cell carcinomaAged 80 and overintegumentary systemPrognostic evaluationMiddle AgedHsp60ImmunohistochemistryKeratoacanthomamedicine.anatomical_structure030220 oncology & carcinogenesisCarcinoma Squamous CellImmunohistochemistryHSP60AdultT cellDifferential diagnosichemical and pharmacologic phenomenaCD1aBiologySettore MED/08 - Anatomia PatologicaDiagnosis DifferentialMitochondrial Proteins03 medical and health sciencesYoung AdultKeratoacantomaImmune systemmedicineBiomarkers TumorHumansAgedRetrospective StudiesOriginal PaperSettore BIO/16 - Anatomia UmanaCD1a; Differential diagnosis; Hsp60; Immunohistochemistry; Keratoacantoma; Prognostic evaluation; Squamous cell carcinoma; Treatment; Biochemistry; Cell BiologyfungiCell BiologyChaperonin 60medicine.diseaseTreatmentstomatognathic diseases030104 developmental biologyCancer researchDifferential diagnosisCarcinogenesisCell stresschaperones
researchProduct

Lipid Antigen Presentation by CD1b and CD1d in Lysosomal Storage Disease Patients

2019

The lysosome has a key role in the presentation of lipid antigens by CD1 molecules. While defects in lipid antigen presentation and in invariant Natural Killer T (iNKT) cell response were detected in several mouse models of lysosomal storage diseases (LSD), the impact of lysosomal engorgement in human lipid antigen presentation is poorly characterized. Here, we analyzed the capacity of monocyte-derived dendritic cells (Mo-DCs) from Fabry, Gaucher, Niemann Pick type C and Mucopolysaccharidosis type VI disease patients to present exogenous antigens to lipid-specific T cells. The CD1b- and CD1d-restricted presentation of lipid antigens by Mo-DCs revealed an ability of LSD patients to induce CD…

0301 basic medicineMaleAntigens CD1d / metabolismMucopolysaccharidosis type VIMonocytes / metabolismLysosomal Storage Diseases / diagnosisAntigens CD10302 clinical medicineAntigens CD1 / metabolismLysosomal storage diseaseImmunology and AllergyChildOriginal ResearchAged 80 and overAntigen PresentationbiologyKiller Cells Natural / metabolism*lipid antigen presentationAntigen Presentation / immunologyMiddle AgedNatural killer T cellLipidsnatural killer T cellsKiller Cells Naturalmedicine.anatomical_structureCD1DDendritic Cells / metabolismChild Preschool*dendritic cellsFemalelipids (amino acids peptides and proteins)*natural killer T cellsDisease SusceptibilitymonocytesAdultlcsh:Immunologic diseases. AllergyAdolescentT cellImmunologyCD1chemical and pharmacologic phenomenaCD1bLysosomal Storage Diseases / metabolismCD1dImmunophenotyping03 medical and health sciencesYoung AdultAntigenLysosomemedicineDendritic Cells / immunologyHumans*monocytesLymphocyte Countdendritic cellslysosomal storage diseasesLysosomal Storage Diseases / etiologyKiller Cells Natural / immunologyAgedbusiness.industry*CD1dInfantlipid antigen presentationmedicine.diseaseMonocytes / immunology*CD1b*lysosomal storage diseases030104 developmental biologyImmunologybiology.proteinAntigens CD1dbusinesslcsh:RC581-607Lipids / immunologyBiomarkers030215 immunology
researchProduct

Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.

2015

Few patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) achieve prolonged disease-free survival. Blinatumomab, a bispecific T-cell engaging antibody construct, transiently links CD3-positive T cells to CD19-positive B cells. This phase 2 study evaluated stepwise (9-28-112 μg/d with weekly dose increases; n = 23) or flat (112 μg/d; n = 2) dosing of blinatumomab by continuous infusion, with dexamethasone prophylaxis, in patients with relapsed/refractory DLBCL. Patients received a median of 3 prior lines of therapy. Median time since last regimen was 1.5 months. Seventeen patients ended treatment in cycle 1 (induction), 7 in cycle 2 (consolidation), and 1 in retreatment. Am…

0301 basic medicineMaleCD3 ComplexClinical Trials and ObservationsSalvage therapyPhases of clinical researchKaplan-Meier EstimateBiochemistryGastroenterologyDexamethasone0302 clinical medicineRecurrenceAntibodies BispecificMedicineMolecular Targeted TherapyFatigueRemission InductionHematologyMiddle AgedTumor Burden030220 oncology & carcinogenesisBlinatumomabFemaleImmunotherapyLymphoma Large B-Cell Diffusemedicine.drugAdultmedicine.medical_specialtyFeverImmunologyAntigens CD19Antineoplastic AgentsDisease-Free SurvivalDrug Administration Schedule03 medical and health sciencesAntigens NeoplasmInternal medicineHumansDosingAdverse effectAgedSalvage TherapyDose-Response Relationship Drugbusiness.industryCell Biologymedicine.diseaseLymphomaSurgeryRegimen030104 developmental biologyNervous System DiseasesbusinessDiffuse large B-cell lymphomaBlood
researchProduct

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis.

2017

Supplemental Digital Content is available in the text.

0301 basic medicineMaleCancer Researchmedicine.medical_treatmentT-LymphocytesEpitopes T-LymphocyteT-Cell Antigen Receptor SpecificityImmunotherapy AdoptiveEpitopeCohort StudiesExon0302 clinical medicineimmune system diseasesImmunology and AllergyMedicineProtein IsoformsChildAged 80 and overbiologyCD19CART-19B-ALLMiddle AgedPrecursor Cell Lymphoblastic Leukemia-Lymphomaepitope-lossmedicine.anatomical_structureTreatment Outcome030220 oncology & carcinogenesisChild PreschoolComputingMethodologies_DOCUMENTANDTEXTPROCESSINGFemaleClone (B-cell biology)Gene isoformAdultAdolescentRecombinant Fusion ProteinsImmunologyAntigens CD19Receptors Antigen T-CellCancer VaccinesCD1903 medical and health sciencesYoung AdultAntigenHumansAgedPharmacologybusiness.industryInfant NewbornisoformsInfantImmunotherapy030104 developmental biologyImmunologybiology.proteinClinical StudyTumor EscapeBone marrowbusinessJournal of immunotherapy (Hagerstown, Md. : 1997)
researchProduct

The janus face of NKT cell function in autoimmunity and infectious diseases

2018

Natural killer T cells (NKT) are a subset of T lymphocytes bridging innate and adaptive immunity. These cells recognize self and microbial glycolipids bound to non-polymorphic and highly conserved CD1d molecules. Three NKT cell subsets, type I, II and NKT-like expressing different antigen receptors (TCR) were described and TCR activation promotes intracellular events leading to specific functional activities. NKT can exhibit different functions depending on the secretion of soluble molecules and the interaction with other cell types. NKT cells act as regulatory cells in the defence against infections but, on the other hand, their effector functions can be involved in the pathogenesis of sev…

0301 basic medicineglycolipidsAutoimmunityReviewAdaptive Immunitymedicine.disease_causeAutoimmunityCatalysiimmunologylcsh:Chemistry0302 clinical medicineT-Lymphocyte Subsetslcsh:QH301-705.5SpectroscopyInnate lymphoid cellhemic and immune systemsComputer Science Applications1707 Computer Vision and Pattern RecognitionGeneral MedicineNKTNatural killer T cellAcquired immune systemComputer Science ApplicationsCell biologyCD1DmicrobesCell typechemical and pharmacologic phenomenaGlycolipidBiologyCD1dCommunicable DiseasesCatalysisInorganic Chemistry03 medical and health sciencesmedicineAnimalsHumansMicrobePhysical and Theoretical ChemistryMolecular BiologyInflammationT-cell receptorOrganic ChemistryModels ImmunologicalAlpha-galactosylceramideAlpha-galactosylceramide; Autoimmunity; CD1d; Glycolipids; Microbes; NKT; Sulfatide; Catalysis; Molecular Biology; Spectroscopy; Computer Science Applications1707 Computer Vision and Pattern Recognition; Physical and Theoretical Chemistry; Organic Chemistry; Inorganic ChemistryImmunity InnateSettore MED/16 - Reumatologia030104 developmental biologylcsh:Biology (General)lcsh:QD1-999biology.proteinNatural Killer T-CellsSulfatideCD8030215 immunology
researchProduct

A double-negative (IgD−CD27−) B cell population is increased in the peripheral blood of elderly people

2009

The T cell branch of the immune system has been extensively studied in the elderly and it is known that the elderly have impaired immune function, mainly due to the chronic antigenic load that ultimately causes shrinkage of the T cell repertoire and filling of the immunologic space with memory T cells. In the present paper, we describe the IgD(-)CD27(-) double-negative B cell population which (as we have recently described) is higher in the elderly. Most of these cells were IgG(+). Evaluation of the telomere length and expression of the ABCB1 transporter and anti-apoptotic molecule, Bcl2, shows that they have the markers of memory B cells. We also show that these cells do not act as antigen…

AdultAgingATP Binding Cassette Transporter Subfamily BT cellAntigens CD19B-Lymphocyte Subsetschemical and pharmacologic phenomenaYoung AdultB lymphocyte Immunosenescence IgD CD27 Elderly Immunologic memorymedicineHumansCytotoxic T cellATP Binding Cassette Transporter Subfamily B Member 1IL-2 receptorCD40 AntigensCD154Antigen-presenting cellCells CulturedAgedAged 80 and overSettore MED/04 - Patologia Generalebusiness.industryAge FactorsHLA-DR AntigensImmunoglobulin DMiddle AgedTelomereFlow CytometryAcquired immune systemTumor Necrosis Factor Receptor Superfamily Member 7B-1 cellKi-67 Antigenmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2ImmunologyB7-1 AntigenbusinessImmunologic MemoryCD80Developmental BiologyMechanisms of Ageing and Development
researchProduct

CD1a down-regulation in primary invasive ductal breast carcinoma may predict regional lymph node invasion and patient outcome.

2008

AIMS: CD1a is a molecule belonging to the highly conserved group of CD1 proteins. Its expression in dendritic cells is related to the presentation of tumour-derived glycolipid antigens to T cells and, consequently, the development of a successful antitumour response. The aim was to investigate the presence of CD1a+ cells in both primary tumours and lymph nodes (LN) of a series of 35 invasive ductal carcinomas by both immunohistochemistry and reverse transcription-polymerase chain reaction. METHODS AND RESULTS: CD1a antigen was more expressed in N0 than N1 breast cancer (P < 0.0001) in both primary lesions and LN metastases and correlated positively and significantly with oestrogen (ER) (P =…

AdultCD4-Positive T-LymphocytesCarcinoma Ductal BreastDown-RegulationBreast NeoplasmsDendritic CellsCD8-Positive T-LymphocytesMiddle AgedCD1APrognosisImmunohistochemistryAntigens CD1Gene Expression Regulation NeoplasticReceptors EstrogenPredictive Value of TestsLymphatic MetastasisHumansFemaleReceptors ProgesteroneAged
researchProduct

CD1a-positive infiltrating-dendritic cell density and 5-year survival from human breast cancer.

2003

Infiltrating CD1a(+) dendritic cells (DCs) have been associated with increased survival in a number of human cancers. This study investigated DC infiltration within breast cancers and the association with survival. Classical established prognostic factors, of tumour size, lymph node status, histological grade, lympho-vascular invasion, the KI-67 (MIB-1) fraction and the Nottingham Prognostic Index (NPI) were also compared. A total of 48 breast cancer patients were followed from the time of surgery and CD1a density analysis for 5 years or until death. Our data set validated previous studies, which show a relationship between survival and the NPI (P0.001), tumour size (P0.01) and lymph node s…

AdultCancer ResearchCellular immunityPathologymedicine.medical_specialtyMammary glandBreast NeoplasmsCD1asurvivalAntigens CD1Breast cancerbreast cancerPredictive Value of Testsmental disordersmedicineHumansskin and connective tissue diseasesAntigen-presenting cellLetter to the EditorSurvival analysisAgedAged 80 and overintegumentary systembusiness.industryMolecular and Cellular PathologyCancerDendritic cellDendritic CellsDuctal carcinomaMiddle Agedmedicine.diseasePrognosisSurvival Analysismedicine.anatomical_structureOncologyCancer researchFemalebusinessBritish journal of cancer
researchProduct